Unity Biotechnology's UBX0101 Phase 2 in knee osteoarthritis (n=183, primary endpoints pain and function at week 12, both missed, August 2021) remains the most direct human test of the systemic senolytic hypothesis, and APAC family-office capital has largely priced past it. The capital moved into senolytic and cellular-rejuvenation programs regardless. Singapore's NRF BioMedical Research Council funds two cellular senescence labs at A*STAR; Hong Kong family-office aging-sector mandates routinely cite the dasatinib-quercetin oral combination as a reference treatment in portfolio briefs. The clinical ledger is a different document. No Phase 3 senolytic trial for any systemic human indication has been registered on ClinicalTrials.gov. Unity's own program did not recover the systemic thesis: UBX1325 (navacapromab), now in Phase 2 for diabetic macular edema, is a Bcl-xL inhibitor working in ocular tissue, a narrower indication with a different mechanism than the cellular-clearance play those portfolio briefs describe.

The biology underneath the UBX0101 failure is specific. Jan van Deursen's clearance experiments used BubR1-hypomorphic mice with constitutively accelerated senescent cell burden, a model that over-represents the pathology relative to normal human aging. The intra-articular MDM2/p53-pathway inhibitor tested in OA patients was a reasonable first translation; the negative result was never answered by a second trial in a different senolytic class. My read: the capital is pricing the mouse clearance curve. The trial that would price the human curve has not been designed. A Phase 3 in a systemic aging indication requires an agreed primary endpoint, and FDA's Office of Tissues and Advanced Therapies has not published guidance on what that endpoint should be; neither PMDA's Division of Cellular and Tissue-based Products nor NMPA's Center for Drug Evaluation has issued a parallel draft.